Recruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.
Eligibility
Sex
ALL
Min age
3 Months
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
* Age from 3 months to 85 years, no sex preference;
* Right heart catheter meet the following conditions simultaneously: mPAP≥25mmHg, and PVR \> 3 Wood units(in children PVRi \> 3 WU x m2), and PAWP≤15 mmHg at rest;
* Patients diagnosed with group 1,2,4,5 PH according to the WHO classification, detailed description is as follows: Pulmonary arterial hypertension, Lung disease / chronic hypoxia associated pulmonary hypertension, Pulmonary hypertension associated with pulmonary artery stenosis / obstruction and Pulmonary hypertension caused by other multiple factors
* Take at least one pulmonary hypertension targeted drug or calcium antagonist;
* Signed written informed consent.
Exclusion Criteria:
* Patients diagnosed with pulmonary hypertension related to left heart disease;
Primary outcome measure(s)
Adverse drug events — through study completion, an average of 6 months
All-cause Mortality — through study completion, an average of 6 months
Trial sites (1)
Facility
City
Region
Status
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing
Beijing Municipality
Recruiting
More China National Center for Cardiovascular Diseases trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.